RMD - ResMed Inc.
| Previous Close | 130.71 |
| Open | 131.40 |
| Bid | 0.00 x 800 |
| Ask | 134.03 x 900 |
| Day's Range | 131.15 - 134.37 |
| 52 Week Range | 90.64 - 141.25 |
| Volume | 717,375 |
| Avg. Volume | 523,785 |
| Market Cap | 19.242B |
| Beta (3Y Monthly) | 0.25 |
| PE Ratio (TTM) | 47.83 |
| EPS (TTM) | 2.80 |
| Earnings Date | Oct 23, 2019 - Oct 28, 2019 |
| Forward Dividend & Yield | 1.56 (1.19%) |
| Ex-Dividend Date | 2019-08-14 |
| 1y Target Est | 122.47 |
- GuruFocus.com
Resmed Inc (RMD) CEO Michael J. Farrell Sold $913,714 of Shares
CEO of Resmed Inc (30-Year Financial, Insider Trades) Michael J. Farrell (insider trades) sold 6,651 shares of RMD on 09/09/2019 at an average price of $137.38 a share. Continue reading...
- Zacks
GNNDY or RMD: Which Is the Better Value Stock Right Now?
GNNDY vs. RMD: Which Stock Is the Better Value Option?
- GuruFocus.com
5 Companies Hit 52-Week Highs
As of late, 5 companies have reached yearly highs Continue reading...
- Zacks
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
Investors' confidence continues to be high on ResMed's (RMD) prospects.
- Business Wire
ResMed Announces Participation in the 17th Annual Morgan Stanley Global Healthcare Conference
ResMed today announced that David Pendarvis, chief administrative officer and global general counsel, will participate in a fireside chat at the 17th Annual Morgan Stanley Global Healthcare Conference on Monday, September 9, 2019, beginning at approximately 2:50 p.m.
- Zacks
ResMed (RMD) Up 6.7% Since Last Earnings Report: Can It Continue?
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
Is Resmed a Buy?
The CPAP pioneer has a phenomenal track record of success, but should investors jump on board today?
- Zacks
ResMed (RMD) Hits a New 52-Week High: What's Driving It?
ResMed (RMD) gains from promising financial results in the fourth quarter of fiscal 2019.
- Motley Fool
3 More Medtech Stocks for Your Watch List
These three companies are pumping fresh air into the lungs of millions all over the world.
- GuruFocus.com
ResMed Inc (RMD) Files 10-K for the Fiscal Year Ended on June 30, 2019
ResMed Inc (RMD) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. ResMed Inc is a part of the healthcare sector. Continue reading...
- Zacks
NUVA vs. RMD: Which Stock Is the Better Value Option?
NUVA vs. RMD: Which Stock Is the Better Value Option?
- Thomson Reuters StreetEvents
Edited Transcript of RMD earnings conference call or presentation 25-Jul-19 8:30pm GMT
Q4 2019 Resmed Inc Earnings Call
- Motley Fool
ResMed Boosts Its Dividend
Revenue and gross margin continue to be strong, but acquisition costs continue to put pressure on the bottom line.
- Zacks
ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
Motley FoolResmed Inc (RMD) Q4 2019 Earnings Call Transcript
RMD earnings call for the period ending June 30, 2019.
- Zacks
ResMed (RMD) Surpasses Q4 Earnings and Revenue Estimates
ResMed (RMD) delivered earnings and revenue surprises of 3.26% and 0.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Medical Products' Earnings Roster for Jul 25: SYK, BAX & More
Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.
- Zacks
Analysts Estimate ResMed (RMD) to Report a Decline in Earnings: What to Look Out for
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GuruFocus.com
Resmed Inc (RMD) President and COO ResMed Inc. Robert Andrew Douglas Sold $511,820 of Shares
President and COO ResMed Inc. of Resmed Inc (30-Year Financial, Insider Trades) Robert Andrew Douglas (insider trades) sold 4,111 shares of RMD on 07/15/2019 at an average price of $124.5 a share. Continue reading...
- Zacks
Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
- GlobeNewswire
MatrixCare Appoints Geriatrician Dheeraj Mahajan as Chief Medical Officer, Executive Vice President
MatrixCare announced today that Dheeraj Mahajan, MD, MBA, MPH, FACP, CMD, CIC, CHCQM, has joined its team as chief medical officer and executive vice president to advance MatrixCare’s vision of creating a seamless continuum where data moves with the patient, connecting both acute and post-acute care providers. Dr. Mahajan joins MatrixCare with more than 15 years as a practicing physician and is a nationally recognized expert and speaker on physician payment models, clinical documentation improvement, denial management, quality measurement in post-acute and long-term care, and transitional care quality improvement.
- GlobeNewswire
Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.
NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
